Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Stock Up 12.1 %

Shares of EVGN stock opened at $2.40 on Thursday. The firm has a fifty day moving average of $3.09 and a 200-day moving average of $5.28. Evogene has a 12-month low of $2.14 and a 12-month high of $10.40. The company has a market capitalization of $98.92 million, a price-to-earnings ratio of -5.22 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.94). The company had revenue of $0.91 million for the quarter. Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.